DRR168509
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.620
- INFLAMMATORY_RESPONSE+0.610
- TNFA_SIGNALING_VIA_NFKB+0.590
- IL6_JAK_STAT3_SIGNALING+0.570
- INTERFERON_ALPHA_RESPONSE+0.570
- ALLOGRAFT_REJECTION+0.560
- COMPLEMENT+0.440
- KRAS_SIGNALING_UP+0.430
- IL2_STAT5_SIGNALING+0.360
- TGF_BETA_SIGNALING+0.260
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- E2F_TARGETS-0.500
- MYC_TARGETS_V1-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.420
- G2M_CHECKPOINT-0.390
- OXIDATIVE_PHOSPHORYLATION-0.390
- DNA_REPAIR-0.380
- MITOTIC_SPINDLE-0.290
- PEROXISOME-0.250
- ADIPOGENESIS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f26d1599-6e75-4c0d-8b40-c7e45fe9da76 | — | — | 0.911 |
| 2 | BS_02NZT8CE | low-grade glioma | — | 0.900 |
| 3 | 6dfa748c-af43-469f-a98b-8472a4132739 | — | — | 0.897 |
| 4 | TCGA-MP-A4TJ-01A-51R-A262-07 | — | cohortA1 | 0.897 |
| 5 | 2d12ea90-c4f4-4aca-b353-360057b446e2 | — | — | 0.894 |
| 6 | BS_CS170P7T | pilocytic astrocytoma | — | 0.887 |
| 7 | TCGA-AC-A2FB-01A-11R-A17B-07 | — | A | 0.886 |
| 8 | SJBT031351_D1.RNA-Seq | EPN | Supratentorial EPN | 0.885 |
| 9 | 98e49cc4-1040-4291-b975-da3e8fc3ddfc | — | — | 0.881 |
| 10 | TCGA-97-7553-01A-21R-2039-07 | — | cohortA1 | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.620 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.610 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.590 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.570 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| COMPLEMENT | 0.440 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.430 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |